SCHEMBL6202870

SCHEMBL6202870

CN1CCCN(C(=O)/C=C/c2c(-c3ccc4c(ccn4C)c3)cc(Sc3cc(-c4ccc5c(ccn5C)c4)c(/C=C/C(=O)N4CCCN(C)CC4)c(Cl)c3Cl)c(Cl)c2Cl)CC1

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ITGB2 P05107 7/20 0.48
ICAM1 P05362 7/20 0.48
ITGAL P20701 7/20 0.48
CCNC P24863 4/20 0.46
CDK8 P49336 4/20 0.46
ALDH1A1 P00352 3/20 0.43
RAB9A P51151 1/20 0.43
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
GAA P10253 1/20 0.39
AR P10275 1/20 0.38
FASN P49327 1/20 0.36
GPR183 P32249 1/20 0.36
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6199405 0.85 ITGB2 (0.53) ITGB2ICAM1ITGALCCNCCDK8
SCHEMBL6197437 0.85 ITGAL (0.66) ITGB2ICAM1ITGALCCNCCDK8
SCHEMBL6219918 0.84 CCNC (0.46) ITGB2ICAM1ITGALCCNCCDK8
SCHEMBL6198429 0.84 ITGB2 (0.54) ITGB2ICAM1ITGALCCNCCDK8
SCHEMBL6197403 0.83 ITGAL (0.55) ITGB2ICAM1ITGALCCNCCDK8
SCHEMBL6196589 0.81 ITGB2 (0.53) ITGB2ICAM1ITGALCCNCCDK8
SCHEMBL6199336 0.81 HTT (0.51) ITGB2ICAM1ITGALCCNCCDK8
SCHEMBL6310320 0.80 ITGB2 (0.51) ITGB2ICAM1ITGALCCNCCDK8
SCHEMBL6198445 0.80 ITGB2 (0.53) ITGB2ICAM1ITGALCCNCCDK8
SCHEMBL6568699 0.79 ITGAL (0.74) ITGB2ICAM1ITGALCCNCCDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050250768-A1 Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds ABBOTT LABORATORIES 2005-11-10 US claimed
EP-1140814-B1 CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS ABBOTT LAB (US) 2005-05-25 EP claimed
US-6878700-B1 Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds ABBOTT LABORATORIES (US) 2005-04-12 US claimed
US-20040116518-A1 Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds ABBOTT LABORATORIES 2004-06-17 US claimed
US-20050250768-A1 Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds ABBOTT LABORATORIES 2005-11-10 US disclosed
EP-1140814-B1 CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS ABBOTT LAB (US) 2005-05-25 EP disclosed
US-6878700-B1 Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds ABBOTT LABORATORIES (US) 2005-04-12 US disclosed
US-6867203-B2 Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds ABBOTT LABORATORIES (US) 2005-03-15 US disclosed
EP-1481968-A2 Cell adhesion-inhibiting anti-inflammatory and immune-suppressive compounds Abbott Laboratories (US) 2004-12-01 EP disclosed
US-20040116518-A1 Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds ABBOTT LABORATORIES 2004-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250768-A1 Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds ICAM1, VCAM1, EPCAM ITGB2 32/4885ICAM1 1/4885ITGAL 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.